Table 4.
Effect of antidrug antibodies (ADAs) on percentage Psoriasis Area and Severity Index (PASI) improvement at week 12 in patients on tildrakizumab 100 mg or 200 mg by ADA patient category
| Dose (mg) | ADA patient category | N | Mean % PASI improvement at week 12 |
|---|---|---|---|
| 100 | Inconclusive | 29 | 80 |
| ADA‐NEG | 603 | 75 | |
| Non‐TE‐POS NAb‐NEG | 33 | 76 | |
| Non‐TE‐POS NAb‐POS | 5 | 68 | |
| TE‐POS NAb‐NEG | 24 | 79 | |
| TE‐POS NAb‐POS | 4 | 62 | |
| 200 | Inconclusive | 255 | 79 |
| ADA‐NEG | 374 | 76 | |
| Non‐TE‐POS NAb‐NEG | 35 | 81 | |
| Non‐TE‐POS NAb‐POS | 6 | 88 | |
| TE‐POS NAb‐NEG | 25 | 81 | |
| TE‐POS NAb‐POS | 4 | 38 |
TE, treatment‐emergent ADA; NAb, neutralizing antibodies; POS, positive; NEG, negative.